Orserdu combinations show favorable safety profiles for ER+, HER2- metastatic breast cancer in phase Ib/II trials

California state-funded institute scraps selection process that put cancer projects at a disadvantage
Cancer researchers are resubmitting applications to the California Institute for Regenerative Medicine

The California Institute for Regenerative Medicine, a state agency tasked with awarding billions of dollars of scientific funding for stem cell and gene therapy, has rescinded a controversial policy that was disrupting the flow of funding to cancer research.

Antidepressant unable to prevent chemotherapy-associated nerve damage, Alliance trial shows

A randomized trial conducted by the Alliance for Clinical Trials in Oncology with support from NCI has found that duloxetine, a medication commonly used to treat chronic pain and psychiatric conditions, does not prevent nerve damage caused by chemotherapy in patients with colorectal cancer.

April 10, 2026

Vol.52 No.14

Clinical Roundup

IMNN-001 improves median OS by over 14 months in newly diagnosed advanced ovarian cancer, phase II study shows

Adding IMNN-001, a DNA-mediated immunotherapy, to standard-of-care treatment improved median overall survival by 14.7 months in patients with newly diagnosed advanced ovarian cancer, final clinical data from the OVATION 2 study shows.

April 03, 2026

Vol.52 No.13

Drugs & Targets

FDA approves Ponlimsi to increase bone mass, including for breast and prostate cancer patients

FDA has approved Ponlimsi (denosumab-adet) as a biosimilar to Prolia.

April 03, 2026

Vol.52 No.13

Clinical Roundup

Combination treatment benefits patients with leptomeningeal metastases from breast cancer, MD Anderson study finds

Patients with leptomeningeal metastasis have historically had few treatment options. Now, researchers from The University of Texas MD Anderson Cancer Center have found a combination of targeted therapies, tucatinib and trastuzumab, plus the chemotherapy drug, capecitabine, may improve symptoms and extend survival in some breast cancer patients with LM.

March 27, 2026

Vol.52 No.12

In Brief

Kathleen N. Moore appointed deputy director and director of Phase I Oncology Trials Program at Fred & Pamela Buffett Cancer Center

The Fred & Pamela Buffett Cancer Center has named Kathleen N. Moore as deputy director and director of Phase I Oncology Trials.

March 20, 2026

Vol.52 No.11

Orserdu combinations show favorable safety profiles for ER+, HER2- metastatic breast cancer in phase Ib/II trials

YOU MAY BE INTERESTED IN

California state-funded institute scraps selection process that put cancer projects at a disadvantage
Cancer researchers are resubmitting applications to the California Institute for Regenerative Medicine

Antidepressant unable to prevent chemotherapy-associated nerve damage, Alliance trial shows

IMNN-001 improves median OS by over 14 months in newly diagnosed advanced ovarian cancer, phase II study shows

FDA approves Ponlimsi to increase bone mass, including for breast and prostate cancer patients

Combination treatment benefits patients with leptomeningeal metastases from breast cancer, MD Anderson study finds

Kathleen N. Moore appointed deputy director and director of Phase I Oncology Trials Program at Fred & Pamela Buffett Cancer Center

Renew today!

Subscriber content

Never miss an issue!

Login

Orserdu combinations show favorable safety profiles for ER+, HER2- metastatic breast cancer in phase Ib/II trials

YOU MAY BE INTERESTED IN

California state-funded institute scraps selection process that put cancer projects at a disadvantageCancer researchers are resubmitting applications to the California Institute for Regenerative Medicine

Antidepressant unable to prevent chemotherapy-associated nerve damage, Alliance trial shows

IMNN-001 improves median OS by over 14 months in newly diagnosed advanced ovarian cancer, phase II study shows

FDA approves Ponlimsi to increase bone mass, including for breast and prostate cancer patients

Combination treatment benefits patients with leptomeningeal metastases from breast cancer, MD Anderson study finds

Kathleen N. Moore appointed deputy director and director of Phase I Oncology Trials Program at Fred & Pamela Buffett Cancer Center

Never miss an issue!

Login

California state-funded institute scraps selection process that put cancer projects at a disadvantage
Cancer researchers are resubmitting applications to the California Institute for Regenerative Medicine